News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
280,021 Results
Type
Article (14560)
Company Profile (57)
Press Release (265402)
Multimedia
Podcasts (74)
Webinars (13)
Section
Business (101349)
Career Advice (468)
Deals (15483)
Drug Delivery (86)
Drug Development (36918)
Employer Resources (50)
FDA (6442)
Job Trends (6263)
News (151272)
Policy (14201)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (458)
Accelerated approval (27)
ADA (11)
Adcomms (9)
Allergies (105)
Alliances (23375)
ALS (76)
Alzheimer's disease (554)
Antibody-drug conjugate (ADC) (187)
Approvals (6805)
Artificial intelligence (302)
ASCO (113)
Autoimmune disease (87)
Automation (22)
Bankruptcy (152)
Best Places to Work (4383)
BIO (24)
BIOSECURE Act (9)
Biosimilars (171)
BioSpace Insights (66)
Biotechnology (27)
Bladder cancer (55)
Brain cancer (41)
Breast cancer (221)
Cancer (1845)
Cardiovascular disease (213)
Career advice (423)
Career pathing (15)
CAR-T (69)
CDC (8)
Cell therapy (209)
Cervical cancer (20)
Clinical research (32881)
Collaboration (1032)
Commercialization (3)
Company closure (2)
Compensation (434)
Complete response letters (51)
COVID-19 (790)
CRISPR (56)
C-suite (719)
Cystic fibrosis (65)
Data (2714)
Decentralized trials (1)
Denatured (19)
Depression (63)
Dermatology (17)
Diabetes (172)
Diagnostics (1495)
Digital health (17)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (189)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (109)
Earnings (34627)
Editorial (25)
Employer branding (4)
Employer resources (46)
Events (40125)
Executive appointments (651)
FDA (7980)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (597)
Gene editing (90)
Generative AI (32)
Gene therapy (210)
GLP-1 (501)
Government (1443)
Grass and pollen (4)
Guidances (177)
Healthcare (3654)
Hematology (66)
HIV (21)
Huntington's disease (13)
IgA nephropathy (61)
Immunology and inflammation (94)
Immuno-oncology (34)
Indications (110)
Infectious disease (892)
Inflammatory bowel disease (89)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (152)
Interviews (59)
IPO (5947)
IRA (33)
Job creations (2061)
Job search strategy (375)
JPM (29)
Kidney cancer (15)
Labor market (39)
Layoffs (216)
Leadership (11)
Legal (3457)
Licensing (6)
Liver cancer (27)
Longevity (11)
Lung cancer (258)
Lymphoma (168)
Machine learning (16)
Management (17)
Manufacturing (631)
Marketing (7)
MASH (93)
Medical affairs (1)
Medical device (1322)
Medtech (1344)
Mergers & acquisitions (10109)
Metabolic disorders (590)
mRNA (66)
Multiple sclerosis (66)
NASH (15)
Neurodegenerative disease (126)
Neuropsychiatric disorders (51)
Neuroscience (1134)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (611)
Now hiring (24)
Obesity (304)
Opinion (154)
Ovarian cancer (69)
Pain (141)
Pancreatic cancer (78)
Parkinson's disease (118)
Partnered (12)
Patents (306)
Patient recruitment (208)
Peanut (15)
People (30438)
Pharmaceutical (33)
Pharmacy benefit managers (19)
Phase 1 (8521)
Phase 2 (13866)
Phase 3 (12553)
Pipeline (4066)
Policy (153)
Postmarket research (1407)
Preclinical (3432)
Press Release (25)
Prostate cancer (123)
Psychedelics (27)
Radiopharmaceuticals (168)
Rare diseases (523)
Real estate (2668)
Recruiting (19)
Regulatory (11646)
Reports (19)
Research institute (583)
Resumes & cover letters (55)
Rett syndrome (12)
RNA editing (9)
RSV (26)
Schizophrenia (89)
Series A (119)
Series B (69)
Service/supplier (1)
Sickle cell disease (62)
Special edition (11)
Spinal muscular atrophy (85)
Sponsored (11)
Startups (1656)
State (2)
Stomach cancer (6)
Supply chain (69)
Tariffs (71)
The Weekly (53)
Vaccines (287)
Venture capital (44)
Weight loss (175)
Women's health (53)
Worklife (4)
Date
Today (53)
Last 7 days (239)
Last 30 days (907)
Last 365 days (10509)
2026 (6733)
2025 (10752)
2024 (12505)
2023 (14285)
2022 (19596)
2021 (20094)
2020 (19045)
2019 (14894)
2018 (11717)
2017 (13897)
2016 (13129)
2015 (15487)
2014 (12443)
2013 (10610)
2012 (11414)
2011 (11963)
2010 (10932)
Location
Africa (325)
Alabama (23)
Alaska (1)
Arizona (95)
Arkansas (4)
Asia (21394)
Australia (2762)
California (4207)
Canada (1907)
China (813)
Colorado (184)
Connecticut (170)
Delaware (177)
Europe (42288)
Florida (806)
Georgia (81)
Hawaii (2)
Idaho (11)
Illinois (487)
India (82)
Indiana (331)
Iowa (2)
Japan (380)
Kansas (89)
Kentucky (21)
Louisiana (7)
Maine (2)
Maryland (531)
Massachusetts (3393)
Michigan (55)
Minnesota (219)
Mississippi (1)
Missouri (41)
Montana (9)
Nebraska (8)
Nevada (20)
New Hampshire (9)
New Jersey (1856)
New Mexico (7)
New York (1202)
North Carolina (782)
North Dakota (2)
Northern California (1996)
Ohio (98)
Oklahoma (5)
Oregon (16)
Pennsylvania (907)
Puerto Rico (18)
Rhode Island (18)
South America (510)
South Carolina (12)
Southern California (1878)
Tennessee (78)
Texas (589)
United States (16621)
Utah (69)
Vermont (1)
Virginia (219)
Washington D.C. (42)
Washington State (307)
West Virginia (1)
Wisconsin (60)
Wyoming (1)
280,021 Results for "braeburn pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Braeburn’s Long-Acting Brixadi Receives FDA Clearance to Treat Opioid Use Disorder
The FDA approved Braeburn Pharmaceuticals’ new buprenorphine treatment option with extended-release medication that could pave the way for greater patient compliance.
May 25, 2023
·
3 min read
·
Lisa Munger
Drug Development
Braeburn Announces Publication of a Post Hoc Analysis of Data from Patients Using Fentanyl Treated with BRIXADI in a Phase 3 Efficacy and Safety Study
Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open.
June 25, 2024
·
12 min read
Press Releases
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Potential near-term commercialization through two synergistic business units: (i) a telehealth platform connecting patients with independent licensed healthcare providers and (ii) a North American network of pharmacy-based pharmaceutical 3D-printing systems for compounding medications, together forming a personalized medicine ecosystem
August 11, 2026
·
8 min read
Press Releases
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
August 6, 2026
·
10 min read
Press Releases
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to attend the live, interactive presentation and one-on-one meetings
June 18, 2026
·
5 min read
Press Releases
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
August 3, 2026
·
15 min read
Press Releases
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
August 14, 2026
·
4 min read
Pharm Country
Braeburn’s BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder
Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD).
May 23, 2023
·
12 min read
Press Releases
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
June 28, 2026
·
5 min read
Press Releases
GNI Group Completes Acquisition of AYUMI Pharmaceutical
July 1, 2026
·
5 min read
1 of 28,003
Next
